Cohance Lifesciences Stock Hits 52-Week Low at Rs. 848.35

Cohance Lifesciences has reached a new 52-week low, hitting Rs. 848.35 today, marking a significant downturn for the small-cap pharmaceutical and biotechnology company. This decline comes after a three-day streak of losses, although the stock managed to outperform its sector by 1.31% today. The intraday high for the stock was recorded at Rs. 870.35, reflecting a modest gain of 2.27%. In terms of moving averages, Cohance Lifesciences is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Over the past year, the stock has experienced a notable decline of 32.75%, contrasting sharply with the Sensex's positive performance of 5.78%. The company's financial metrics reveal a challenging landscape, with a low operating profit growth rate of 2.95% over the last five years and a significant drop in quarterly profit after tax. Additionally, all promoter shares are pledged, which may contribute to the stock's downward pressure in a declining market.